» Articles » PMID: 21843598

DARPP-32 and Akt Regulation in Ethanol-preferring AA and Ethanol-avoiding ANA Rats

Overview
Journal Neurosci Lett
Specialty Neurology
Date 2011 Aug 17
PMID 21843598
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Ethanol and other addictive drugs affect many intracellular phosphorylation and dephosphorylation cascades. These cascades are thought to be highly important in the regulation of neuronal activity. The present experiments characterized the regulation of three key signaling molecules, DARPP-32 (dopamine and cAMP regulated phosphoprotein, 32kDa), Akt kinase and ERK1/2 (extracellular signal-regulated kinase 1 and 2) in ethanol-preferring AA (Alko, alcohol) and ethanol-avoiding ANA (Alko, non-alcohol) rat lines. Radioactive in situ hybridization was used in drug naïve animals and Western blotting after acute ethanol administration in striatum, hippocampus and prefrontal cortex. The mRNA levels of DARPP-32 in striatal areas were higher in ANA rats than in AA rats. There was no difference in the striatal enriched phosphatase (STEP61), the downstream target of DARPP-32 expression between the rat lines. Ethanol (1.5g/kg) increased phosphorylation of DARPP-32 at threonine 34 in both AA and in ANA rats indicating that acute ethanol activates DARPP-32 similarly in these rat lines. The expression of Akt kinase was higher in the CA1 of hippocampus in ANA than in AA rats and acute ethanol activated Akt in hippocampus in ANA but not in AA rats. No significant alterations in the regulation of ERK1/2 were found in either rat line. Our findings suggest that DARPP-32 and Akt are regulated by ethanol and differences in the regulation of these molecules might contribute to the dramatically different ethanol drinking patterns seen in AA and ANA rats.

Citing Articles

Exploring the Role of DARPP-32 in Addiction: A Review of the Current Limitations of Addiction Treatment Pathways and the Role of DARPP-32 to Improve Them.

Greener M, Storr S NeuroSci. 2024; 3(3):494-509.

PMID: 39483434 PMC: 11523713. DOI: 10.3390/neurosci3030035.


Epistatic evidence for gender-dependant slow neurotransmission signalling in substance use disorders: PPP1R12B versus PPP1R1B.

Liu K, Zhao J, Chen C, Xu J, Bell R, Hall F EBioMedicine. 2020; 61:103066.

PMID: 33096475 PMC: 7581882. DOI: 10.1016/j.ebiom.2020.103066.


Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects.

El-Saber Batiha G, Alqahtani A, Ilesanmi O, Saati A, El-Mleeh A, Hetta H Pharmaceuticals (Basel). 2020; 13(8).

PMID: 32824399 PMC: 7464486. DOI: 10.3390/ph13080196.


Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders.

Khoja S, Huynh N, Warnecke A, Asatryan L, Jakowec M, Davies D Psychopharmacology (Berl). 2018; 235(6):1697-1709.

PMID: 29500584 PMC: 5949264. DOI: 10.1007/s00213-018-4869-9.


Molecular Mechanism: ERK Signaling, Drug Addiction, and Behavioral Effects.

Sun W, Quizon P, Zhu J Prog Mol Biol Transl Sci. 2016; 137:1-40.

PMID: 26809997 PMC: 5330621. DOI: 10.1016/bs.pmbts.2015.10.017.